ANKTIVA Long-Term Data: 84% Avoid Cystectomy at Three Years, Responses Past 53 Months
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio published long-term QUILT-3.032 data in the Journal of Urology showing ANKTIVA plus BCG produced a 71% complete response rate in BCG-unresponsive NMIBC with CIS, a median CR duration of 26.6 months, and responses extending beyond 53 months. 84% of responders avoided cystectomy at three years and disease-specific survival hit 98.2%, with no Grade 4 or 5 treatment-related adverse events. The data lands two days after the FDA expanded ANKTIVA's label to papillary-only disease, reinforcing the durability story behind the drug's commercial ramp. ImmunityBio posted record Q2 product revenue of $50.7M (up 92% year-over-year) but still carries a going concern warning and a $863M net loss, so sustained ANKTIVA uptake is the swing factor for the equity. The publication is a peer-reviewed validation rather than a new regulatory or commercial event, so the near-term trading impact is modest.
At the time of this announcement, IBRX was trading at $9.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.